Grifols stock steadies as investors weigh 2025 results

Grifols stock (ISIN ES0171996087) is being judged against 2025 numbers that set a clear baseline: revenue reached EUR 7.06 billion, adjusted EBITDA was EUR 1.63 billion, and net profit came in at EUR 177 million. The company also reported net debt of EUR 9.16 billion at year-end 2025, a level that keeps balance-sheet execution central for investors.

2025 numbers set the tone

Grifols said in its investor-relations materials that 2025 revenue was EUR 7.06 billion and adjusted EBITDA was EUR 1.63 billion, putting the EBITDA margin at about 23.1%. Net profit of EUR 177 million was a sharp turnaround from the EUR 609 million loss reported for 2024, which gives the latest annual comparison a clear positive swing.

That comparison matters because the gap between 2024 and 2025 was not a small adjustment. It was a difference of EUR 786 million in bottom-line performance, and it came alongside a year-end net debt figure of EUR 9.16 billion that still leaves financing discipline in the spotlight.

Debt remains the pressure point

The 2025 debt figure is the number that investors keep returning to, because it is large relative to annual earnings power even after the profit recovery. With adjusted EBITDA at EUR 1.63 billion and net debt at EUR 9.16 billion, the net-debt-to-EBITDA ratio is roughly 5.6 times on a simple year-end basis.

That ratio is not a valuation conclusion, but it is a useful reference point. It shows why the market tends to focus on cash generation, deleveraging, and the durability of earnings rather than only on the headline profit rebound.

Revenue above EUR 7 billion

Grifols reported revenue of EUR 7.06 billion for 2025, which confirms the scale of the plasma-derived medicines business. The same annual update showed adjusted EBITDA of EUR 1.63 billion and net profit of EUR 177 million, so the income statement improved across several layers at once.

For investors, the more relevant question is how much of that improvement can be sustained in 2026. A business that produces more than EUR 7 billion in annual sales can support de-leveraging, but only if cash conversion and operating margin remain steady.

Product mix still matters

Grifols is best known for plasma-derived therapies, where volume, pricing, and collection efficiency all feed into the annual earnings profile. The company’s latest investor-relations update indicates that the group now has enough scale to show margin leverage, but also enough debt that every quarter still matters.

The practical takeaway is simple: the 2025 profit recovery is real, yet the balance sheet means the next phase is about consistency rather than one-off improvement. That is why the market tends to read the annual numbers together instead of focusing on revenue or profit alone.

Grifols stock and the market view

Grifols stock is still best read through a combination of earnings recovery and leverage. A company that moved from a EUR 609 million loss in 2024 to a EUR 177 million profit in 2025 has a different operating profile from a year earlier, but the EUR 9.16 billion net-debt figure prevents the story from becoming purely celebratory.

Without a fresh price quote in this article, the most useful market anchor is the company’s own annual performance and capital structure. That gives a clearer lens on Grifols than a short-term headline move would, because the numbers already show both progress and constraints.

Plasma therapies drive the story

Grifols builds its business around plasma-derived medicines and related services, which makes the company sensitive to collection volumes, production efficiency, and reimbursement trends. That operating model explains why annual revenue scale and EBITDA margin are so closely watched.

On the 2025 figures, the company showed EUR 7.06 billion in revenue and EUR 1.63 billion in adjusted EBITDA, which suggests the core business is generating enough earnings to matter. The remaining question is how much of that earnings base can be directed toward lowering net debt.

Debt and earnings in focus

Net debt of EUR 9.16 billion at 31 December 2025 remains the balancing item in the story. Against that backdrop, the move from a EUR 609 million loss in 2024 to a EUR 177 million profit in 2025 is useful because it demonstrates that earnings power is moving in the right direction.

That said, the company still has to convert accounting profit into cash and keep leverage moving lower. For a business with Grifols stock exposure, that is the metric set that matters most: sales, EBITDA, profit, and debt, all in the same frame.

Annual result snapshot

The 2025 annual update is the most useful product reference point here because it is the freshest full-year evidence in the company’s own materials. It captures the scale of the plasma business and gives investors a cleaner look at the earnings recovery than a standalone quarterly print would.

In practical terms, that means the business case now rests less on a single headline and more on whether the company can keep revenue above EUR 7 billion while reducing leverage from the EUR 9.16 billion net-debt level.

Closing view on Grifols stock

Grifols stock currently looks like a leverage-and-earnings story more than a pure growth story. The company’s 2025 figures - EUR 7.06 billion in revenue, EUR 1.63 billion in adjusted EBITDA, EUR 177 million in net profit, and EUR 9.16 billion in net debt - give the market enough substance to measure progress without guessing at the next step.

The annual comparison is the key signal: profit improved from a EUR 609 million loss in 2024 to a EUR 177 million gain in 2025, while debt still keeps the financing profile tight. That combination is why Grifols remains a numbers-first stock story.